New White Paper! Exploring New Markets to Boost Plant Capacity Utilization

Posted by Fuld + Company on Nov 30, 2015 9:28:31 AM

While our micro case studies have proven popular, sometimes an engagement warrants a deeper look.

For instance, determining which markets to enter is a critical decision. Syndicated research reports can't provide insights specifically tailored to a single organization's objectives and capabilities.

Read More

Topics: Consumer Goods, Fuld + Company, Market Analysis, New Market Entry

New White Paper! New Strategies for Health Care Industry Convergence

Posted by Fuld + Company on Nov 23, 2015 8:00:00 AM

Consumer retail, enterprise IT, consumer electronics, health insurance, and health care delivery are rapidly converging to improve the customer/patient experience. 

Relying on tried and true approaches to strategy development may no longer be good enough when multiple markets collide. As health care delivery, payment, and reporting evolve in response to shifts in demographics, technology, and political influence, population health management becomes the key to controlling costs.

Read More

Topics: Fuld + Company, Market Analysis, Scenario Analysis, Technology/Telecomm, Healthcare, Industry Convergence, Competitive Strategy

New White Paper! Millennials: Predictors of Future Disruptions

Posted by Fuld + Company on Nov 5, 2015 12:35:05 PM

If you've been following us this past summer, you'll know Fuld + Company Founder Leonard Fuld spent some of those sunny days on the Rose Fitzgerald Kennedy Greenway. He was seeking insight into the minds of millennials, the demographic that will comprise 75% of the U.S. workforce in just 10 years. How did they feel about Uber, Amazon, and Obamacare? Were they shocked by Blackberry's demise? What did they want their weddings to look like?

The five surveys he conducted are now available in one white paper, Millennials: Predictors of Future Disruptions.

Read More

Topics: Brand Insights, Innovation, Market Analysis, Fuld, Leonard, Competitive Strategy

Pfizer’s Xeljanz: An Uphill Battle

Posted by Adi Reske on Oct 28, 2015 9:32:16 AM

Approx. 6 million people in the US have plaque psoriasisOn October 14th, 2015, Pfizer announced receipt of a Complete Response Letter (CRL) from the FDA regarding its recent supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib) in moderate to severe plaque psoriasis.

The FDA accepted Pfizer’s filing in February 2015 based on data from the Phase III Oral treatment Psoriasis Trials (OPT) Program. A global, multi-study, clinical development program, OPT was designed to evaluate Xeljanz 5 mg and 10 mg twice daily in patients with the skin disorder.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Life Sciences, Competitive Strategy

Dell Acquires EMC: Heavy Clouds, No Rain

Posted by Ken Sawka on Oct 27, 2015 12:06:53 PM

On October 12, Dell announced its plans to acquire EMC Corporation for $67 billion
, the largest technology industry deal to date, a deal clearly intended to bolster Dell’s ability to compete in the increasingly lucrative corporate data center market. This move follows HP’s split into two organizations which itself was engineered to free HP’s enterprise business from the low-margin shackles of its consumer PC and printer business.  While the Dell-EMC deal will accelerate the transition of corporate data assets to the cloud, the new entity could face significant challenges that hamper its ability to make it rain. 

Our experience conducting war games for Global Fortune 100 companies and analyzing competition in enterprise IT has made it clear that the market is undergoing a dramatic transformation. Our analysis, conducted over an extensive period of time and involving a variety of players, demonstrates that this transformation is characterized by several confluent factors that the combined EMC-Dell will have to navigate to achieve success: 

Read More

Topics: Competitive Intelligence, War Games, Brand Insights, Market Analysis, Technology/Telecomm, Merger and Acquisition

Jack Bauer and the Flu

Posted by Robert Flynn on Oct 23, 2015 6:49:12 AM

On February 5, 2015, Public Health England announced that the flu vaccine had demonstrated low effectiveness against the main strain of flu that had circulated this past winter. Dr. Michael Skinner of Imperial College London, said in response, “Trying to predict which seasonal flu vaccine to produce each year must be a bit like a Jack Bauer car chase in Los Angeles…bound to prove somewhat hit & miss.” 

A similar miss occurred in 2004, when the United States suspended The Chiron Corporation’s shipment of 48 million doses of vaccine, citing problems at the company’s Liverpool, England, manufacturing plant.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Scenario Analysis, Healthcare, Life Sciences, Merger and Acquisition

Holiday Gaming - Microsoft's Big Chance

Posted by Robert Flynn on Oct 13, 2015 9:00:00 AM

If Satya Nadella, CEO of Microsoft, has his way, packages under the Christmas tree and exchanged during Chanukah will be full of boxes containing Xbox consoles and games. To increase gaming revenues, he's made some organizational moves assigning Phil Spencer as head of Xbox and Xbox Live, reporting to Windows chief Terry Myerson. But internal changes will not be sufficient in this huge, highly competitive and fast-paced market, especially given Microsoft's slow growth relative to competitors, a laggard performance largely driven by the impact of mobile gaming.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, New Market Entry, Scenario Analysis, Technology/Telecomm, Industry Convergence, Merger and Acquisition, Product Positioning, Competitive Strategy

The Tweet Heard ‘Round the Pharmaceutical World: A Perspective On Pharmaceutical Drug Pricing

Posted by Alexis Kuchins on Oct 5, 2015 3:22:18 PM

A week ago, presidential candidate Hillary Clinton tweeted her intentions, if elected, to try to curb the rising costs of pharmaceuticals. The plan would place a monthly cap on the out-of-pocket cost that chronic pain patients would have to pay for prescription medications, a greater emphasis on bringing biotechnology-style drugs to the market, and encourage increased use of generic and imported drugs.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, New Market Entry, Pharma, Scenario Analysis, Healthcare, Industry Convergence, Life Sciences, Product Positioning, Competitive Strategy

Companion Diagnostic Strategy: Who Bears Those Costs?

Posted by Alexis Kuchins on Sep 28, 2015 4:25:04 PM

The 2015 World CDx conference in Boston, Massachusetts brought together thought leaders from pharma, diagnostics, and companion diagnostic companies (CDx). This dynamic group of individuals engaged in a dialogue on areas such as next generation sequencing and companion diagnostics, precision medicine, and the regulatory landscape. In conversation with participants and presenters there was a consistent theme of seeking to understand companion diagnostic strategy and who will bear those costs.

Read More

Topics: Competitive Intelligence, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, Medical Devices, Pharma, Scenario Analysis, Healthcare, Life Sciences

Automotive Disruption: Fines Doubled in Construction Zone

Posted by Robert Flynn on Sep 23, 2015 1:27:32 PM

While it was a boat that President Obama used to explore the Alaskan scenery, it is the automobile industry that should sit up and take notice. One anticipated result of the President’s trip, and ongoing international negotiations, is increased environmental regulation that would impact automobile manufacturers. Shifting consumer demand, expanding access to customer data, increased merger and acquisition activity and international regulatory changes are creating market uncertainty that needs to be explored and understood through robust scenario-based planning analysis. Shareholders will expect no less.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Market Analysis, New Market Entry, Scenario Analysis, Industry Convergence, Merger and Acquisition, Competitive Strategy

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.